You are listening to the Draper Fisher-Jervinson Entrepreneurial Thought Leader Seminar,

brought to you weekly by Stanford Technology Ventures Program at Stanford University School of Engineering.

Today I have the privilege of introducing our speaker today, Joe McCracken.

Joe's filling in for Sue Hellman, who's the president of product development at Genentech.

She was called away having to testify in a court case that got continued on the East Coast,

so she didn't get to escape the lawyers.

But we have Joe filling in for, and Joe is head of business development for Genentech, and has been

at Genentech for about seven years now, took a little bit of a break prior to that, and then

was one of the early people at Genentech starting in 1983. So he has a long history at Genentech.

I'm sure many of you know Genentech, but if you don't, I think you'll find Joe's stock

pretty interesting. Genentech is one of those companies that's been able to do some really, have some great

financial performance, but has also stayed true to values around delivering real, real

value to very sick people. So it's a combination of a social mission with a great financial

performance. So without talking more, let me introduce

Joe to you.

Thanks, thanks very much.

Well, first, I'd also like to extend Dr. Sue Helman, she's my boss. I'd like to extend

her regrets that she couldn't be with you here today. Believe me, she would much rather have

been here than where she is.

But I'm delighted to be here and to talk to some of you about Genentech.

I looked at the program and I say that most of your speakers in this program are from the information technologies,

electronics world. But I'm going to talk about health care and biology, which is what Genentech is all about

...